Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain

被引:28
作者
Duan, Jing-jing
Ma, Ji-hua [1 ]
Zhang, Pei-hua
Wang, Xian-pei
Zou, An-rou
Tu, Dan-na
机构
[1] Wuhan Univ Sci & Technol, Coll Med, Cardio Electrophysiol Res Lab, Wuhan 430081, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Cardiovasc Dis,Dept Cardiol,Res Ctr Ion C, Wuhan 430022, Peoples R China
关键词
verapamil; HERG; K+ channel; voltage clamp;
D O I
10.1111/j.1745-7254.2007.00562.x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: The objectives of this study were to investigate the inhibitory action of verapamil on wild-type(WT) and mutation HERG K+ channel current (I-HERG), and to determine whether mutations in the S6 region are important for the inhibition of I-HERG by verapamil. Methods: HERG channels (WT, Y652A, and F656A) were expressed in oocytes of Xenopus laevis and studied using the 2-electrode voltage-clamp technique. Results: WT HERG is blocked in a concentration-dependent manner by verapamil (half-maximal inhibition concentration [IC50]=5.1 mu mol/L), and the steady state activation and inactivation parameters are shifted to more negative values. However, mutation to Ala of Y652 and F656 located on the S6 domain produced 16-fold and 20-fold increases in IC50 for I-HERG blockade, respectively. Simultaneously, the steady state activation and inactivation parameters for Y652A are also shifted to more negative values in the presence of the blockers. Conclusion: Verapamil preferentially binds to and blocks open HERG channels. Tyr-652 and Phe-656, 2 aromatic amino-acid residues in the inner (S6) helix, are critical in the verapamil-binding site.
引用
收藏
页码:959 / 967
页数:9
相关论文
共 23 条
  • [1] AMIYA K, 2001, MOL PHARM, V60, P244
  • [2] Toward a pharmacophore for drugs inducing the long QT syndrome:: Insights from a CoMFA study of HERG K+ channel blockers
    Cavalli, A
    Poluzzi, E
    De Ponti, F
    Recanatini, M
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) : 3844 - 3853
  • [3] Cavero I, 2000, Expert Opin Pharmacother, V1, P947, DOI 10.1517/14656566.1.5.947
  • [4] Chouabe C, 1998, MOL PHARMACOL, V54, P695
  • [5] De Ponti F, 2002, DRUG SAFETY, V25, P263
  • [6] CALCIUM CHANNELS - MOLECULAR PHARMACOLOGY, STRUCTURE AND REGULATION
    HOSEY, MM
    LAZDUNSKI, M
    [J]. JOURNAL OF MEMBRANE BIOLOGY, 1988, 104 (02) : 81 - 105
  • [7] Long QT syndrome: Cellular basis and arrhythmia mechanism in LQT2
    January, CT
    Gong, QM
    Zhou, ZF
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2000, 11 (12) : 1413 - 1418
  • [8] Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367
  • [9] A structural basis for drug-induced long QT syndrome
    Mitcheson, JS
    Chen, J
    Lin, M
    Culberson, C
    Sanguinetti, MC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) : 12329 - 12333
  • [10] Mitcheson JS, 2003, CURR OPIN DRUG DISC, V6, P667